KR102778690B1 - 글리코겐 합성효소 키나아제 3 베타 억제제로서 1h-인다졸-3-카복사마이드 화합물 - Google Patents
글리코겐 합성효소 키나아제 3 베타 억제제로서 1h-인다졸-3-카복사마이드 화합물 Download PDFInfo
- Publication number
- KR102778690B1 KR102778690B1 KR1020207030163A KR20207030163A KR102778690B1 KR 102778690 B1 KR102778690 B1 KR 102778690B1 KR 1020207030163 A KR1020207030163 A KR 1020207030163A KR 20207030163 A KR20207030163 A KR 20207030163A KR 102778690 B1 KR102778690 B1 KR 102778690B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- indazole
- alkyl
- mmol
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18171084 | 2018-05-07 | ||
| EP18171084.9 | 2018-05-07 | ||
| PCT/EP2019/061532 WO2019215075A1 (en) | 2018-05-07 | 2019-05-06 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210005863A KR20210005863A (ko) | 2021-01-15 |
| KR102778690B1 true KR102778690B1 (ko) | 2025-03-12 |
Family
ID=62134122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207030163A Active KR102778690B1 (ko) | 2018-05-07 | 2019-05-06 | 글리코겐 합성효소 키나아제 3 베타 억제제로서 1h-인다졸-3-카복사마이드 화합물 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11472795B2 (enExample) |
| EP (1) | EP3790873B1 (enExample) |
| JP (1) | JP7411574B2 (enExample) |
| KR (1) | KR102778690B1 (enExample) |
| CN (1) | CN112135821B (enExample) |
| AU (1) | AU2019265606B2 (enExample) |
| BR (1) | BR112020021922A2 (enExample) |
| CA (1) | CA3094896A1 (enExample) |
| CY (1) | CY1125293T1 (enExample) |
| DK (1) | DK3790873T3 (enExample) |
| EA (1) | EA202092422A1 (enExample) |
| ES (1) | ES2913975T3 (enExample) |
| GE (2) | GEP20227437B (enExample) |
| HR (1) | HRP20220664T1 (enExample) |
| HU (1) | HUE058894T2 (enExample) |
| IL (1) | IL278330B2 (enExample) |
| LT (1) | LT3790873T (enExample) |
| MA (1) | MA52557A (enExample) |
| MD (1) | MD3790873T2 (enExample) |
| MX (1) | MX2020011882A (enExample) |
| PL (1) | PL3790873T3 (enExample) |
| PT (1) | PT3790873T (enExample) |
| RS (1) | RS63255B1 (enExample) |
| SG (1) | SG11202009230WA (enExample) |
| SI (1) | SI3790873T1 (enExample) |
| SM (1) | SMT202200227T1 (enExample) |
| UA (1) | UA128089C2 (enExample) |
| WO (1) | WO2019215075A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4079732A4 (en) * | 2019-12-16 | 2023-10-18 | Korea Research Institute of Chemical Technology | NEW INDAZOLE DERIVATIVE AND ITS USE |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| JP7746384B2 (ja) * | 2020-12-08 | 2025-09-30 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１のベンゾピラゾール阻害剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0667867A1 (en) | 1992-11-05 | 1995-08-23 | Smithkline Beecham Plc | Piperidine derivatives as 5-ht4 receptor antagonists |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| ITMI20030287A1 (it) | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| ITMI20030972A1 (it) | 2003-05-15 | 2004-11-16 | Acraf | Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende. |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| IN2014CN02646A (enExample) * | 2011-09-14 | 2015-08-07 | Samumed Llc | |
| BR112014018657B1 (pt) | 2012-02-21 | 2022-08-02 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Compostos de 1h-indazol-3-carboxamida |
| AU2013224302B2 (en) | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| EP3755696B1 (en) * | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
-
2019
- 2019-05-06 ES ES19721295T patent/ES2913975T3/es active Active
- 2019-05-06 CA CA3094896A patent/CA3094896A1/en active Pending
- 2019-05-06 RS RS20220482A patent/RS63255B1/sr unknown
- 2019-05-06 HR HRP20220664TT patent/HRP20220664T1/hr unknown
- 2019-05-06 MA MA052557A patent/MA52557A/fr unknown
- 2019-05-06 SI SI201930227T patent/SI3790873T1/sl unknown
- 2019-05-06 GE GEAP201915506A patent/GEP20227437B/en unknown
- 2019-05-06 DK DK19721295.4T patent/DK3790873T3/da active
- 2019-05-06 EP EP19721295.4A patent/EP3790873B1/en active Active
- 2019-05-06 PL PL19721295T patent/PL3790873T3/pl unknown
- 2019-05-06 KR KR1020207030163A patent/KR102778690B1/ko active Active
- 2019-05-06 SM SM20220227T patent/SMT202200227T1/it unknown
- 2019-05-06 LT LTEPPCT/EP2019/061532T patent/LT3790873T/lt unknown
- 2019-05-06 MX MX2020011882A patent/MX2020011882A/es unknown
- 2019-05-06 US US17/051,352 patent/US11472795B2/en active Active
- 2019-05-06 SG SG11202009230WA patent/SG11202009230WA/en unknown
- 2019-05-06 PT PT197212954T patent/PT3790873T/pt unknown
- 2019-05-06 MD MDE20210228T patent/MD3790873T2/ro unknown
- 2019-05-06 HU HUE19721295A patent/HUE058894T2/hu unknown
- 2019-05-06 EA EA202092422A patent/EA202092422A1/ru unknown
- 2019-05-06 GE GEAP202215506A patent/GEAP202215506A/en unknown
- 2019-05-06 CN CN201980029405.9A patent/CN112135821B/zh active Active
- 2019-05-06 UA UAA202006085A patent/UA128089C2/uk unknown
- 2019-05-06 BR BR112020021922-3A patent/BR112020021922A2/pt unknown
- 2019-05-06 AU AU2019265606A patent/AU2019265606B2/en active Active
- 2019-05-06 WO PCT/EP2019/061532 patent/WO2019215075A1/en not_active Ceased
- 2019-05-06 JP JP2020562568A patent/JP7411574B2/ja active Active
- 2019-05-06 IL IL278330A patent/IL278330B2/en unknown
-
2022
- 2022-05-26 CY CY20221100366T patent/CY1125293T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2726115C1 (ru) | Пиридопиримидиновые ингибиторы cdk2/4/6 | |
| KR102206318B1 (ko) | 화학 물질 | |
| CN114423751B (zh) | 用作选择性aurora a抑制剂的新型杂环化合物 | |
| AU2004313928A1 (en) | Heterocyclic protein kinase inhibitors and uses thereof | |
| JP6283688B2 (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン | |
| CA2860466C (en) | Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| KR102778690B1 (ko) | 글리코겐 합성효소 키나아제 3 베타 억제제로서 1h-인다졸-3-카복사마이드 화합물 | |
| BR112014018655B1 (pt) | Composto de 1h-indazol-3-carboxamida, e, composição farmacêutica | |
| EP3882242A1 (en) | Compound inhibiting yap-tead binding, and pharmaceutical composition for preventing or treating cancer, comprising compound as active ingredient | |
| CN115667226A (zh) | 作为egfr抑制剂的三环化合物 | |
| JPWO2006008874A1 (ja) | アミノチアゾ−ル骨格を有するＣｄｋ４、６選択的阻害剤 | |
| WO2002002550A1 (en) | Novel pyrazinone derivatives | |
| JP2023551272A (ja) | ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途 | |
| CN101265274B (zh) | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 | |
| HK40038633A (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| HK40038633B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| EA043429B1 (ru) | 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов киназы гликогенсинтазы 3-бета | |
| KR102344185B1 (ko) | 신규한 Pim 키나아제 억제제 및 이의 용도 | |
| HK40072682A (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| HK40066473B (en) | Novel heterocyclic compounds useful as aurora a selective inhibitors | |
| HK40078921A (en) | Tricyclic compounds as egfr inhibitors | |
| HK40002986A (zh) | 吡啶并嘧啶酮cdk2/4/6抑制剂 | |
| KR20120003958A (ko) | 푸린 유도체 및 이를 사용하는 항종양제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201020 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220329 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240513 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250120 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250305 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250306 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |